This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): BMS-741672
Description: BMS-741672 is an oral, CCR2 antagonist. CCR2 is a receptor for various monocyte chemoattractant proteins, which are involved in the inflammatory process. Chronic inflammation in adipose tissue may play a role in insulin resistance associated with obesity, and monocyte chemoattractant protein 1 (MCP-1) is increased in adipose tissue and the circulation in association with obesity. In a preclinical study (unrelated to this particular drug), chronic increases in circulating MCP-1 induced insulin resistance, macrophage infiltration into adipose tissue, and an increase in hepatic triacylglycerol content.
Additional information available to subscribers only: